SAN FRANCISCO, April  21, 2026  (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ((&#34;Olema&#34; or &#34;Olema Oncology&#34;, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and

OLMA

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Pharmaceuticals to Present Key Clinical Data at ASCO 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN FRANCISCO, April  21, 2026  (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ((&amp;#34;Olema&amp;#34; or &amp;#34;Olema Oncology&amp;#34;, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Olema Pharmaceuticals will showcase initial clinical results for its OP-3136 drug at ASCO 2026, potentially strengthening its competitive positioning in the breast cancer treatment market. Additionally, insights from the OPERA-02 Phase 3 trial will provide further visibility into Olema&#039;s pipeline advancements. Positive reception could bolster investor confidence and price momentum.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Olema to present Phase 1 OP-3136 data at ASCO annual meeting.</li><li>Initial data demonstrates promising results in advanced solid tumors.</li><li>OPERA-02 Phase 3 trial poster to be presented; highlights ongoing research.</li><li>Palazestrant also undergoing pivotal Phase 3 research for breast cancer.</li><li>Company aims to transform treatment standards for ER+ breast cancer.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Olema Pharmaceuticals (OLMA)</strong>: Focus on upcoming ASCO event could impact stock positively.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The disclosures from Olema align with &#039;Corporate Developments&#039; as they revolve around clinical trial presentations at a major oncology event. Such insights often influence investor decisions regarding the viability of drug candidates and the company&#039;s growth potential.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive ASCO presentation outcomes could drive stock price increase.</li><li>Investor sentiment may improve with strong trial data announced at ASCO.</li><li>Phase 3 trial progress further validates Olema’s development pipeline.</li><li>Palazestrant&#039;s FDA Fast Track designation enhances strategic valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ASCO Annual Meeting: May 29 - June 2, 2026, in Chicago.</li><li>Phase 1 OP-3136 data presentation scheduled for May 30, 2026.</li><li>OPERA-02 trial Phase 3 data to be showcased on June 1, 2026.</li><li>Palazestrant is under FDA Fast Track for ER+/HER2- breast cancer.</li><li>OP-3136 targets an epigenetic area in advanced solid tumors.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy OLMA as upcoming ASCO presentations could boost investor sentiment and share price.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN FRANCISCO, April  21, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=j5clxyXWs0p8ciBdtIMUu3aKvjPlnIGnANy34DupFhafVxa-Typ8zvGcvY8jIISGhlQqeFGY7Fv8zOhgGywlh1wBoP0GJVqFrgLD7fYUOfU=" rel="nofollow" target="_blank">Olema Pharmaceuticals, Inc.</a> (("Olema" or "Olema Oncology", NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OLMA">OLMA</a>), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The Company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial.</p>  <p><em>Poster Presentation Details </em><br></br>Title: A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2− advanced breast cancer (ABC): Preliminary results<br></br>Abstract Number: 3088<br></br>Poster Number: 225<br></br>Date/Time: May 30, 2026 from 1:30pm-4:30pm CT / 2:30pm-5:30pm ET</p>  <p>Title: OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2- advanced breast cancer<br></br>Abstract Number: TPS1152<br></br>Poster Number: 261b<br></br>Date/Time: June 1, 2026 from 1:30pm-4:30pm CT / 2:30pm-5:30pm ET</p>  <p>Additional information can be found on the <a href="https://www.globenewswire.com/Tracker?data=1o0cWiDIEwekfD1HC6ES6GarLNrVMcIVXoUl__F-XWfnURKvVlBmk7wEOaRn5W4Pwho_gEwxpZDnJchWGYdRTnNQobW72YKYUprwrfJjZV7E_l252OZxF08FRP9EW3oU" rel="nofollow" target="_blank">ASCO Annual Meeting website</a>.</p>  <p><strong>About Olema Oncology</strong><br></br>Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit <a href="http://www.olema.com" title="www.olema.com">www.olema.com</a>.</p>  <p><strong>About Palazestrant (OP-1250)</strong><br></br>Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.</p>  <p><strong>About OP-3136</strong><br></br>OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.</p>  <p><strong>Forward Looking Statements</strong><br></br>Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "anticipate," "believe," "could," "expect," "goal," "intend," "may," "on track," "potential," "upcoming," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics including but not limited to safety, tolerability, activity, efficacy and therapeutic effects of palazestrant or OP-3136 and the combinability of palazestrant or OP-3136 with other drugs. Because such statements deal with future events and are based on Olema's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled "Risk Factors" in Olema's Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.</p>  <p><strong>Media and Investor Relations Contact</strong><br></br>Courtney O'Konek<br></br>Vice President, Corporate Communications<br></br>Olema Oncology<br></br><a href="https://www.globenewswire.com/Tracker?data=FaQ7u0lBkX74sw7CNMqermp9oUMWP4Yaw55AImLaRVHSCckZb3bQRTUQLTsgIuRGgn8uca8Wy3otFGbzBcVmYw==" rel="nofollow" target="_blank">media@olema.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5NDA1OCM3NTQ3NDEwIzIyMDM1MTU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YWE0MmYyNmUtOTExZS00MzA3LTlkN2YtMWVmN2U1YWE3Mjc0LTEyMTUwNjgtMjAyNi0wNC0yMS1lbg==/tiny/Olema-Pharmaceuticals-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/9c736753-c905-4bd1-ac3a-1444bea84331"><img src="https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png" border="0" width="150" height="43" alt="Primary Logo"></img></a></p>

Olema Pharmaceuticals will showcase initial clinical results for its OP-3136 drug at ASCO 2026, potentially strengthening its competitive positioning in the breast cancer treatment market. Additionally, insights from the OPERA-02 Phase 3 trial will provide further visibility into Olema's pipeline advancements. Positive reception could bolster investor confidence and price momentum.

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News